反応式
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][C:11]2([CH2:22][C:21](=[O:23])[C:20]3[C:15](=[CH:16][CH:17]=[C:18](B4OC(C)(C)C(C)(C)O4)[CH:19]=3)[O:14]2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].Cl[C:34]1[CH:42]=[CH:41][C:37]([C:38]([NH2:40])=[O:39])=[CH:36][N:35]=1.C([O-])([O-])=O.[Na+].[Na+]>O1CCOCC1.C(Cl)(Cl)Cl.O.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[C:38]([C:37]1[CH:41]=[CH:42][C:34]([C:18]2[CH:19]=[C:20]3[C:15](=[CH:16][CH:17]=2)[O:14][C:11]2([CH2:12][CH2:13][N:8]([C:6]([O:5][C:1]([CH3:4])([CH3:2])[CH3:3])=[O:7])[CH2:9][CH2:10]2)[CH2:22][C:21]3=[O:23])=[N:35][CH:36]=1)(=[O:39])[NH2:40]参加物
8
反応物 3
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 100 °C
実験手順
1′-tert-butoxycarbonyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[chroman-2,4′-piperidin]-4-one (40.0 g, 90.0 mmol), 6-chloronicotinamide (17.0 g, 108 mmol), Pd(PPh3)4 (5.21 g, 4.51 mmol), and aqueous 2M Na2CO3 (100 ml) solution were suspended in dioxane (300 ml) and heated at 100° C. for 16 h. The reaction mixture was diluted with CHCl3 and H2O, the aqueous layer was extracted with CHCl3. The combined organic layer was washed with brine, dried over MgSO4 and silicagel. The desiccant was removed through celite filtration and the filtrate was concentrated under reduced pressure. The resulting residue was purified by crystallization (CHCl3-EtOAc) to obtain the intended compound as a colorless solid.
後処理
- extractionthe aqueous layer was extracted with CHCl3
- washThe combined organic layer was washed with brine
- dry with materialdried over MgSO4 and silicagel
- customThe desiccant was removed through celite filtration
- concentrationthe filtrate was concentrated under reduced pressure
- customThe resulting residue was purified by crystallization (CHCl3-EtOAc)
出典と根拠
- ORDレコード
- ord-71529f5fb4fa4deb990dc0de44b47136
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08524730B2
関連ノート
読み込み中…